255 related articles for article (PubMed ID: 30653490)
1. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
[TBL] [Abstract][Full Text] [Related]
2. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
5. AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Burza S; Mahajan R; Kazmi S; Alexander N; Kumar D; Kumar V; Lasry E; Harshana A; de Lima Pereira A; Das P; Verma N; Das VNR; Lal CS; Rewari B; Goyal V; Rijal S; Alves F; Gill N; Pandey K
Clin Infect Dis; 2022 Oct; 75(8):1423-1432. PubMed ID: 35147680
[TBL] [Abstract][Full Text] [Related]
6. Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Adriaensen W; Cuypers B; Cordero CF; Mengasha B; Blesson S; Cnops L; Kaye PM; Alves F; Diro E; van Griensven J
EBioMedicine; 2020 May; 55():102748. PubMed ID: 32361248
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
Khalil EA; Weldegebreal T; Younis BM; Omollo R; Musa AM; Hailu W; Abuzaid AA; Dorlo TP; Hurissa Z; Yifru S; Haleke W; Smith PG; Ellis S; Balasegaram M; EL-Hassan AM; Schoone GJ; Wasunna M; Kimutai R; Edwards T; Hailu A
PLoS Negl Trop Dis; 2014; 8(1):e2613. PubMed ID: 24454970
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
11. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
[TBL] [Abstract][Full Text] [Related]
12. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
13. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Patole S; Burza S; Varghese GM
Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
[TBL] [Abstract][Full Text] [Related]
14. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Omollo R; Alexander N; Edwards T; Khalil EA; Younis BM; Abuzaid AA; Wasunna M; Njoroge N; Kinoti D; Kirigi G; Dorlo TP; Ellis S; Balasegaram M; Musa AM
Trials; 2011 Jun; 12():166. PubMed ID: 21718522
[TBL] [Abstract][Full Text] [Related]
16. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
[TBL] [Abstract][Full Text] [Related]
17. Visceral Leishmaniasis and HIV coinfection in East Africa.
Diro E; Lynen L; Ritmeijer K; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2869. PubMed ID: 24968313
[TBL] [Abstract][Full Text] [Related]
18. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
Kip AE; Blesson S; Alves F; Wasunna M; Kimutai R; Menza P; Mengesha B; Beijnen JH; Hailu A; Diro E; Dorlo TPC
J Antimicrob Chemother; 2021 Apr; 76(5):1258-1268. PubMed ID: 33677546
[TBL] [Abstract][Full Text] [Related]
19. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
Burza S; Mahajan R; Sinha PK; van Griensven J; Pandey K; Lima MA; Sanz MG; Sunyoto T; Kumar S; Mitra G; Kumar R; Verma N; Das P
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3053. PubMed ID: 25101665
[TBL] [Abstract][Full Text] [Related]
20. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
